(Q39906123)

15 September 2017

title

Knowns and unknowns in the future of multiple sclerosis treatment (English)

1 reference

15 September 2017

0 references

1 reference

1

Olaf Stüve

1 reference

15 September 2017

publication date

1 December 2009

1 reference

Journal of the Neurological Sciences

15 September 2017

published in

1 reference

15 September 2017

volume

287 Suppl 1

1 reference

15 September 2017

page(s)

S30-6

1 reference

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

The Will Rogers phenomenon: the effect of different diagnostic criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Oral fingolimod (FTY720) for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Interferon-beta: mechanism of action and dosing issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Glatiramer acetate: mechanisms of action in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Oral laquinimod therapy in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Current therapeutic recommendations in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Immune surveillance in multiple sclerosis patients treated with natalizumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971298-5

10.1016/S0022-510X(09)71298-5

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference